Before partnering to form Shapiro & Delaney, Elsa Shapiro and Kathleen Delaney worked together for 17 years at the University of Minnesota in the clinical and research assessment of children with various neurological conditions. Having worked with a broad range of disorders, they bring experience in measuring methods in cognition and behavior and their associations with biomarkers, neuroimaging, EEG, and other tools. They have collaborated with other disciplines in measuring outcomes of hematopoietic cell transplantation, enzyme replacement, intrathecal delivery of enzyme, and other treatments.
Elsa G. Shapiro, Ph.D., A.B.P.P. (American Board of Examiners in Professional Psychology); She is Professor of Pediatrics and Neurology, Division of Pediatric Behavioral Neuroscience, University of Minnesota, Minneapolis, MN. She is retired, but remains a part-time faculty member. She has a Ph.D. in Psychology from the University of Minnesota and took her internship and post-doctoral training at National Children's Medical Center in Washington DC. She founded and directed (1974-2006) the pediatric neuropsychology division at the University of Minnesota.
Dr. Shapiro is internationally known for research in neurocognitive and neurobehavioral manifestations of genetic neurodegenerative disorders, and also their relationship to neuroimaging and other surrogate markers.
She has developed methods of longitudinal assessment of neurocognitive functions, delineated the neurocognitive phenotypes of several genetic disorders, studied the relationship between quantitative neuroimaging and neuropsychology in treated and untreated children, and examined the characteristics of dementia in children with neurodegenerative disease. She has more than 90 peer-reviewed publications and invited chapters. She has developed and published tests and measures for preschool and impaired children. She was the co-Principal Investigator of the NIH-supported Lysosomal Disease Network and Principal Investigator of Longitudinal Studies of Brain Structure and Function in the Mucopolysaccharidoses until 2014. She was also co-Principal Investigator of a Natural History study of Sanfilippo syndrome. She has been consulting on neurocognitive endpoints in patients with rare diseases for more than 10 years. Her expertise is broad with special interests in lysosomal and peroxisomal diseases.
Dr. Shapiro also has a strong interest in the effects of poverty on the developing brain and previously led a large study of the effects of lead burden and other social and biological variables on the cognitive development of high-risk inner city children and has consulted on the effects of cerebral malaria and HIV on neurodevelopment in African children.
In addition to her research, she was the founder of the Pediatric Neuropsychology training program at the University of Minnesota in 1974, trained many post-doctoral fellows and directed the autism program for several years. She has mentored 11 fellows and junior faculty in research in neurodegenerative diseases.
She has conducted workshops and given lectures on cognitive and behavioral endpoints around the world, presented to the FDA and EMA and was the 2017 WORLDsymposia keynote presenter.
In December 2016 Dr. Shapiro chaired an international consensus conference to determine cognitive endpoints in MPS disorders. This conference, attended by the FDA and EMA and sponsored by eighteen pharmaceutical companies, produced expert statements that will be published in the first quarter 2017.
Kate Delaney, CSP, CCRC, is a consultant to the biotechnology and pharmaceutical industry in pediatric orphan diseases. This work includes consultation on neurocognitive assessment and regulatory work as it relates to patient advocacy and patient engagement. Ms. Delaney holds a degree in Child Psychology with certifications in psychometry (NAP) and in clinical research (ACRP). Until recently and for 17 years Ms. Delaney was Senior Psychometrist, and Research Program Manager in the Division of Pediatric Clinical Neuroscience at the University of Minnesota, Minneapolis. She has a long track record of work specializing in patients with mucopolysaccharidoses and other neurodegenerative conditions, and has held the role of lead psychometrist for the Neurocognitive and Neuroimaging Longitudinal Study (MPS I, II and VI) of the Lysosomal Disease Network sponsored by the National Institutes of Health and co-sponsored by the National MPS Society and several pharmaceutical companies. She has expertise in the developmental assessment of preschool and school age children with severe cognitive and behavioral impairments and spent hundreds of hours working with families as the primary psychometrist for the Natural History of Sanfilippo Syndrome clinical trials for Shire pharmaceutical company. She has multiple publications in the field including one outlining assessment methods in children and young adults with serve impairment for the purposes of long term outcome evaluation. Ms. Delaney is a consultant on neurocognitive testing, protocol development, data issues, and training in children with lysosomal storage diseases, leukodystrophies, and other medical conditions. She has advised and lectured nationally and internationally and is a consultant across the industry to several biopharmaceutical companies.
Overseeing operations, Jennifer Greenberg brings expertise in diverse project management, communications and development to Shapiro & Delaney. She is adept at managing complex projects and teams. Her extensive work directing programs and steering initiatives to increase stakeholder buy-in brings value to Shapiro & Delaney’s commitment to the client.